Enterprise Europe Network

Novel in vitro diagnosis or prognosis of malignant melanoma

Country of origin:
Country: 
SPAIN
Opportunity:
External Id: 
TOES20210929003
Published
29/09/2021
Last update
04/10/2021
Expiration date
05/10/2022

Keywords

Partner keyword: 
Cytology, Cancerology, Oncology
Diagnostics, Diagnosis
Gene - DNA Therapy
Diagnostic services
In-vitro diagnostics
Oncology
EXPRESS YOUR INTEREST

Summary

Summary: 
A Spanish university together with a genomics research institute have identified a new group of single nucleotide polymorphisms related to the risk and aggressiveness of malignant melanoma. An in vitro method was developed for the diagnosis or prognosis of malignant melanoma and to determine whether these patients respond adequately to a treatment. The entities are looking for companies working in the field of oncology interested in licensing this patented technology.

Description

Description: 

Malignant melanoma (MM), whose prevalence has been increasing in recent years, is the most aggressive form of skin cancer and represents the leading cause of death from skin diseases.

The intratumoral heterogeneity and the complexity of the current status of germline mutations in this type of cancer make it complex to design therapeutic strategies. In this sense, there is a medical need to find reliable biomarkers for an early diagnosis and prognosis of MM, which will facilitate adequate monitoring of the disease, a correct choice of treatment and the control of its subsequent response.

In this sense, researchers from a Spanish university and a genomics research institute have identified eight risk single nucleotide polymorphisms (SNPs). SNPs are related to melanoma, proposing them for use as biomarkers and gene signatures of this condition, aiding earlier identification and thus shortening the time to initiation of treatment.

These promising markers form the basis of the in vitro method developed that allows a diagnosis of MM in patients at risk or with signs of suffering it from a simple biological sample (skin tissue, saliva, blood, urine, serum or plasma). As well, it assesses whether patients who are being treated respond to such therapy. Thus, the presence of at least one of these SNPs or a high expression level in specific genes are considered indications that the individual has MM, has a poor prognosis or is responding poorly to treatment.

Therefore, this method is an aid to improve precision medicine for MM patients and their closest relatives.

Both entities are looking for partners from companies related to diagnostic testing in the field of oncology and malignant melanoma, which are interested in licensing this technology.

Advantages & innovations

Cooperation plus value: 
• It enables early diagnosis of MM and its prognosis. This method and the eight risk SNPs identified facilitate earlier identification of the disease and its prognosis, thus reducing the time to initiation of treatment. • Assessment of response to treatment. In patients diagnosed with melanoma who are treating, the proposed method makes it possible to know whether or not the patient is responding to such therapy. • Improved precision medicine. The proposed in vitro method helps to be more accurate in diagnosing melanoma patients and their closest relatives, making easier the choice of the appropriate treatment for each individual. • The biological sample to be analyzed is easily accessible: skin tissue, saliva, blood, urine, serum or plasma. • No specific equipment is required. The genotyping of SNPs and the quantification of the expression levels of these biomarkers is carried out by PCR and/or qPCR, currently popular and well known techniques, generally common and accessible in laboratories of the sector. • Simple method. The possibility of using a kit or device makes it easier to obtain useful data for the diagnosis and prognosis of this type of melanoma.

Stage of development

Cooperation stage dev stage: 
Under development/lab tested

Partner sought

Cooperation area: 
The entities are looking for partners from companies related to diagnostic testing in the field of oncology and malignant melanoma, which are interested in licensing this technology.

Type and size

Cooperation task: 
SME 11-50,SME <10,>500 MNE,251-500,SME 51-250,>500

figura_ficha_english.png

Diagnostic workflow